Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer Aviation Inc (ACHR) vs Cassava Sciences Inc (FLNA) Price & Performance

Archer Aviation Inc
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

Archer Aviation Inc vs Cassava Sciences Inc — how do they compare? Archer Aviation Inc trades at $4.88 (market cap $3.76B), while Cassava Sciences Inc trades at $1.33 (market cap $63.04M). The key difference: Archer Aviation Inc is far larger — about 59.6× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.

ACHRFLNA
Market Cap
$3.76B$63.04M
Sector
IndustrialsHealth
52-Week High
$13.64$4.64
52-Week Low
$4.68$1.16
Enterprise Value
$2.11B-$23.53M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer Aviation Inc

Archer Aviation (ACHR) trades at $5.37, up 7.83% with a bearish technical signal despite recent momentum. The company shows severe financial strain with -$618.2M net income on minimal $300K revenue in 2025, though analyst sentiment remains optimistic with 78% buy ratings. Recent news highlights progress toward FAA certification for its Midnight eVTOL aircraft, with commercialization targeted for 2028 and a $6B order book providing long-term potential.

The stock presents high-risk speculative potential with significant execution hurdles. While regulatory progress and major partnerships with United Airlines and Stellantis support the bullish case, persistent cash burn and negative margins require substantial capital raises. Investors face binary outcomes dependent on successful certification and commercial deployment timelines against intense competition in the emerging eVTOL market.

Cassava Sciences Inc

FLNA trades at $1.31, up 6.5% today, with a bearish technical signal but recent quarterly earnings beats. The company, focused on therapies for Tuberous Sclerosis Complex-related epilepsy, reported a net loss of $90.97 million in 2025, with negative cash flow from operations. Analyst consensus is bullish with 8 buy ratings out of 12, and recent news highlights business updates and scientific presentations.

The outlook is mixed: strong analyst support and clinical progress offer upside potential, but persistent losses, negative cash flow, and high financial risks pose significant challenges. Investors should weigh the speculative growth prospects against the substantial operational deficits and market volatility.

Returns comparison

Trailing returns across standard periods

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

Read more on ACHR

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA